Navigation Links
Cord Blood America Restructures Debt; Projects to be Cash Flow Positive
Date:2/25/2009

SANTA MONICA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced an agreement with Shelter Island Opportunity Fund to restructure its current outstanding debt.

"The restructuring is a major step forward for Cord Blood America. With the signing of the agreement, Cord Blood America projects it will become cash flow positive for the first time in its history," said Matthew Schissler, Founder and CEO. "We anticipate formally being able to announce this when we file our quarterly numbers for period ending June 30, 2009."

"We have emphasized to our shareholders that reducing debt is a major focus in 2009," Mr. Schissler said. "This agreement provides us the opportunity to follow through on our commitment." The Company recently announced that since the beginning of 2009, it has reduced long term debt by more than $1 million.

"The storage of stem cells is a predictable, high margin revenue stream business with little bad debt," Mr. Schissler continued. "The loan originally helped CBAI to acquire a large customer base with the CorCell acquisition, giving us consistent cash flow. The principals of Shelter Island Opportunity Fund worked with us to restructure our debt, putting us in position to run as a cash flow positive organization. This is a gesture of true partnering with CBAI, while sharing the stem cell vision to become a globally dominant stem cell storage company."

Mr. Schissler also stressed that the entire stem cell sector and its investors await the announcement from the Obama Administration lifting the current ban on Federal funding for research on embryonic stem cell lines. "Continued progress and potential additional discoveries in the use of stem cells in treating diabetes, heart disease, and other major diseases will dramatically increase the number of families storing umbilical cord blood stem cells, the focus of our business," Mr. Schissler said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting
2. Cord Blood Announces $1 Million Reduction in Long Term Debt
3. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
4. ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services
5. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
6. NicOx Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
7. Cord Blood America Salutes President-Elect Obamas Promise to Lift Restrictions on Stem Cell Research
8. Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon
9. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
10. Publication on Tregitopes in Blood Journal of October 2008
11. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... -- In five studies being presented today during the 58th ... in San Diego , researchers are ... of life-saving treatments to patients with a variety of ... therapies directly to the sites in the body where ... advantage over traditional, systemic methods. The studies highlight the ...
(Date:12/2/2016)... ... 02, 2016 , ... In anticipation of AxioMed’s exclusive cleanroom ... company President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. ... Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma Research ... the MMRF CoMMpass Study SM —the largest and most ... medicine in multiple myeloma—will be presented at the 58 ... & Exposition in San Diego ... optimize treatment strategies, as well as identify pathways and ...
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):